Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stromal Cells in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients;~* Aged 18 or older;~* Living-donor (related and unrelated, spouse/husband) kidney transplant recipients;~* Non-Human Leukocyte Antigen (HLA) identical with the donor (one or two haplotype mismatches);~* First kidney transplant;~* Capable of understanding the purpose and risk of the study;~* Written informed consent.~Exclusion Criteria:~* MSC donor positive for HIV-1, HIV-2, hepatitis B virus (HBV),hepatitis C virus (HCV), syphilis;~* Specific contraindication to MSC infusion;~* Any clinical relevant condition that might affect study participation and/or study results;~* Pregnant women and nursing mothers;~* Unwillingness or inability to follow study protocol in the investigator's opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesenchymal Stromal Cells (Type: EXPERIMENTAL): A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).